Patents Represented by Attorney, Agent or Law Firm Raymond J. Lillie
  • Patent number: 7541443
    Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: June 2, 2009
    Assignees: Tolerrx, Inc., Isis Innovation, Ltd., Cambridge University Technical Services, Ltd.
    Inventors: Mark Frewin, Herman Waldmann, Scott Gorman, Geoff Hale, Patricia Rao, Tadeusz Kornaga, Douglas Ringler, Stephen Cobbold, Dawn Winsor-Hines
  • Patent number: 6835377
    Abstract: For repair of cartilage damaged as part of the degenerative effects of osteoarthritis, the inventors have found that the human mesenchymal stem cell approach makes it possible to: (1) regenerate both shallow cartilage chondral defects and full thickness cartilage defects (osteochondral lesions); (2) broaden the suitable clinical population to routinely include middle-aged patients; (3) eliminate the use of autologous tissue grafts (mature cartilage and the periosteal covering) to repair an articular cartilage injury; (4) regenerate other types of injured cartilage such as patellar and spinal disk cartilage; (5) regenerate articular joint cartilage in older patients with osteoarthritis; and (6) form new cartilage and subchondral bone which fully integrate into the adjacent normal tissue.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: December 28, 2004
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Victor M. Goldberg, Arnold I. Caplan, Francis P. Barry, David J. Fink, Daniel R. Marshak, James S. Burns
  • Patent number: 6825033
    Abstract: Methods of treating tumors, preventing restenosis, and treating hyperplasias, corneal haze, and cataracts by administering to an animal a mutated cyclin G1 protein. The mutated cyclin G1 protein may be administered to an animal by administering to an animal an expression vehicle, such as a retroviral vector comprising a gene construct encoding a mutated cyclin G1 protein.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 30, 2004
    Assignee: University of Southern California
    Inventors: Erlinda Maria Gordon, Frederick L. Hall
  • Patent number: 6814950
    Abstract: Bimodal inorganic material that in a pore size distribution plot has distinct mesopore and micropore peaks. A process for producing a bimodal material or a material that contains essentially only mesopores involves heating an inorganic oxide in the presence of material that bonds to the inorganic oxide by hydrogen bonding. The micropores may or may not include a crystalline structure.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: November 9, 2004
    Assignees: ABB Lummus Global Inc., Technische Universiteit Delft
    Inventors: Zhiping Shan, Thomas Maschmeyer, Jacobus Cornelis Jansen
  • Patent number: 6809055
    Abstract: An improved zeolite having a high number of strong acid sites wherein said zeolite has an AAI of at least 1.0. In a preferred embodiment, such zeolite is produced by controlling conditions after production of the crystalline structure such that loss of tetrahedral aluminum is minimized to thereby provide a zeolite with the above defined AAI.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: October 26, 2004
    Assignee: ABB Lummus Global, Inc.
    Inventors: Rudolf Overbeek, Nelleke van der Puil, Chuen Y. Yeh, Lawrence L. Murrell, Yun-Feng Chang, Philip Jay Angevine, Johannes Hendrik Koegler
  • Patent number: 6797269
    Abstract: The present invention provides a method to modulate immune responses using antigen presenting human mesenchymal stem cells to induce specific T cell anergy. The present invention also provides a method to modulate immune responses using human mesenchymal stem cells as a platform to express molecules which will induce T cell anergy.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: September 28, 2004
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Joseph D. Mosca, Kevin R. McIntosh
  • Patent number: 6761887
    Abstract: Disclosed are a composition of chemically defined components which support in vitro and in vivo chondrogenesis of mesenchymal stem cells, a method for in vitro and in vivo chondrogenic induction of such stem cells, and a method of forming human chondrocytes in vitro and in vivo from such stem cells.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: July 13, 2004
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Karl Kavalkovich, Raymond Boynton, Mary Murphy, Frank Barry
  • Patent number: 6761884
    Abstract: A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: July 13, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael Blaese, W. French Anderson, Jeanne R. McLachlin, Yawen L. Chiang, Martin Eglitis
  • Patent number: 6727396
    Abstract: Ethylene and hexene-1 are produced from butene-1 by metathesis of butene-1 and isomerization of the hexene-3 produced therein to hexene-1. The initial starting material is a mixed butene stream wherein butene-1 is isomerized to butene-2 with isobutylene being separated therefrom, followed by isomerization of butene-2 to butene-1, with the butene-1 being the feed to the metathesis.
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: April 27, 2004
    Assignee: ABB Lummus Global, Inc.
    Inventor: Robert J. Gartside
  • Patent number: 6709864
    Abstract: A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid, a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor), and/or a compound which upregulates peroxisome proliferator activated receptor &ggr; (PPAR &ggr;) expression and/or increases its binding affinity to its DNA binding site. The process can further include isolating the adipocytes from remaining hMSCs.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: March 23, 2004
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen C. Beck
  • Patent number: 6703209
    Abstract: This invention provides a method of using a porcine stem cell factor (PSCF), which may also be termed porcine “steel” factor, which is preferably membrane-bound PSCF on transfected murine STO feeder cells, for establishing pluripotent or totipotent porcine cell lines, especially for the culture of porcine primordial germ cells (PGCs).
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: March 9, 2004
    Assignee: Biotransplant, Inc.
    Inventors: Manfred Baetscher, Gottfried Brem
  • Patent number: 6691969
    Abstract: Described is an apparatus for adjusting the inclination of a seat squab (12) of a vehicle seat (10), wherein the device (18) has a rocker (20) with an upper and a lower rocker element (22, 24) which are pivotably movably connected together by lateral bearing bushes (36). Fixed to the upper rocker element (22) is a toothed bridge (38) with mutually oppositely disposed bridge tooth arrangements (40) which are concentric with respect to the bearing bushes (36). Provided between the two bridge tooth arrangements (40) of the toothed bridge (38) are two toothed sliders (64) with slider tooth arrangements (66). Provided between the two toothed sliders (64) is a locking member (48) rotatable about a rotary axis (26) extending through the bearing bushes (36). The two toothed sliders (64) are linearly movably guided on the lower rocker element (24) between a locking position and a release and adjusting position.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: February 17, 2004
    Assignee: Grammer AG
    Inventors: Hans-Dieter Fretschner, Stefan Graf, Richard Ott, Holger Raum
  • Patent number: 6692743
    Abstract: Although the mechanism of induction of apoptosis through antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells is well understood, little is known about the fate of the reactive NK cells. Nevertheless, it has been shown that NK cells previously activated by IL-2, but not naive NK cells, died by apoptosis after Fc&ggr;RIIIa crosslinking, or after engagement in cytolytic functions. It is demonstrated that apoptosis of naive NK cells is also observed after stimulation with a rat IgG2b anti CD2 mAb (LO-CD2a/BTI-322) or anti HLAI (LO-HLA-1)mAb. The NK apoptosis is rapid (within minutes), Fas-ligand and mRNA synthesis independent and does not require a cell contact. The intracellular mechanism of NK cell apoptosis is calcium, PKC and PLA2 dependent but calcineurin and P13 kinase independent. We suggest that NK cell apoptosis results from the crosslinking on the same cell surface of CD2 or HLA-I molecules and Fc&ggr;RIIIa that exhibits a high affinity for the rat IgG2b isotype.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: February 17, 2004
    Assignee: Universite Catholique de Louvain
    Inventors: Herve Bazin, Dominique Latinne
  • Patent number: 6685936
    Abstract: A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of suppressor T cells effective to reduce or inhibit host rejection of the transplant. The suppressor T cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with suppressor T cells.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: February 3, 2004
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Kevin McIntosh, Elena Klyushnenkova
  • Patent number: 6644737
    Abstract: A vehicle seat comprises a seat squab supported on a base structure, and a spring arrangement for weight adjustment, the spring arrangement being connected to a weight adjustment actuating device. Associated with the actuating device is a level indicator device for indicating adjustment of the seat squab to the seat squab level which optimally corresponds to the weight of the respective seat occupant, in relation to the spring travel of the seat squab. The level indicator device and the actuating device are provided at least substantially centrally at the front edge of the seat squab for optimum actuability and adjustability.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: November 11, 2003
    Assignee: Grammer AG
    Inventors: Josef Kohl, Manfred Meier, Holger Raum
  • Patent number: 6624115
    Abstract: A product comprised of a three dimensional network of material is coated with a particulate support. The coating may be applied by an electrophoretic coating procedure to apply a particulate coating on the surface or into the interior portions of such three dimensional network of material. In one embodiment, the particles are a catalyst or a catalyst precursor or a catalyst support to thereby provide a catalyst structure in which catalyst may be supported as a coating in the interior and on the exterior of a three-dimensional network of material having a high void volume. Edge effects may be reduced by control or disruption of field lines during the coating. In addition, larger particles may be electrophoretically coated onto a product by the use of smaller particles which function as a “glue”.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: September 23, 2003
    Assignee: ABB Lummus Global, Inc.
    Inventors: Lothar Schuh, Heidemarie Gutzeit, Philipp Herschel
  • Patent number: 6616932
    Abstract: A liquid pharmaceutical for oral delivery wherein at the time of use, a solid unit dosage form is added to the liquid wherein the unit dosage form is comprised of a substrate soluble in the liquid and a particulate pharmaceutically active material in a pharmaceutically effective amount. At the time of use, the unit dosage form is added to the liquid, without requiring measurement of the liquid, and the entire liquid is consumed to provide for oral delivery of the pharmaceutically effective amount of material.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: September 9, 2003
    Assignee: Delsys Pharmaceutical Corporation
    Inventors: Suggy S. Chrai, Ramaswamy Murari
  • Patent number: 6609757
    Abstract: A vehicle seat includes a backrest with a forearm support carried thereon at the rear side thereof, the aim being to improve the level of comfort for the user of the seat in a position of facing rearwardly.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: August 26, 2003
    Assignee: Grammer AG
    Inventors: Richard Ott, Nikolaus Haller, Hermann Meiller
  • Patent number: 6557936
    Abstract: An integrated child's seat (10) is provided for a motor vehicle seat. The child's seat (10) is displaceable between a low and an unfolded raised position. It has a base portion (12) and a support portion (14) which are pivotably connected by front and rear parallelogram arm devices (16, 18). A diagonal strut device (40) is linearly movably guided with a guide end portion (42) along a guide device (44) provided on the support portion (14) or on the front parallelogram arm device (16). The diagonal strut device (40) is pivotably connected with its second end portion (52) to the rear parallelogram arm device (18) by a pivotal connection (58). The rear parallelogram arm device (18) has a weak crash location (38) so that in the unfolded condition of the child's seat (10) with a corresponding weight on the support portion (14), the rear parallelogram arm device (18) buckles at the weak crash location (38) and the support portion (14) dips downwardly with its rear end part.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: May 6, 2003
    Assignee: Grammer AG
    Inventors: Norbert Augsberger, Gerhard Gebert, Gerhard Delling, Peter Kirchner, Erwin Haller
  • Patent number: 6554359
    Abstract: A sprung vehicle seat has a base member and a top member, and a scissor support assembly operatively disposed therebetween. The scissor support assembly comprises first and second pivotably interconnected scissor levers. Secured to the first scissor levers is a sliding guide in the form of a plate member which is oriented in the longitudinal direction of the seat. A spring member bears against the sliding guide and the top member and is displaceable in the longitudinal direction of the seat for the purposes of weight adjustment of the seat.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: April 29, 2003
    Assignee: Grammer AG
    Inventors: Josef Kohl, Hermann Meiller